Seagen Inc. announced updated efficacy and safety results from Part C of a phase 2 single-arm trial evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma.
